The Decision Resources Biosimilars Advisory Service Analyst Call

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser

Biosimilars Advisory Service Analyst Call

Substitution and Interchangeability: Physician Perspectives and Market Impact

— An Analyst Call from Decision Resources’ Biosimilars Advisory Service

As part of our Biosimilars Advisory Service, Decision Resources is offering an exclusive analyst call entitled Substitution and Interchangeability: Physician Perspectives and Market Impact. This analyst call is open ONLY to subscribers of Decision Resources’ Biosimilars Advisory Service.

Please contact us to learn how you can purchase this service and attend the analyst call.

According to Decision Resources’ research in biosimilars, an important market forecast assumption is that pharmacy-level substitution of a branded biologic for a biosimilar will not occur in major pharmaceutical markets. This assumption has an enormous impact on the corporate and competitive dynamics of the biosimilars landscape and has recently been put to the test in Norway. This analyst call will examine physician perspectives on pharmacy-level substitution and explore an alternative forecast should current assumptions change.

This analyst call, presented by Decision Resources Director Michael Malecki, Ph.D., will answer the following questions:

Where do we stand today with respect to substitution and interchangeability, and how does our current status inform our forecast assumptions?
How do our forecast assumptions with respect to substitution influence other market forecast assumptions?
How do physicians view pharmacy-level substitution across specialties?
How would our market forecast change if we revised our assumptions regarding pharmacy-level substitution? How much more money would brands lose to biosimilars?

Registration: Biosimilars Advisory Service Analyst Call

Substitution and Interchangeability: Physician Perspectives and Market Impact

July 7, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase the Biosimilars Advisory Service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Webinar Details

Date & Time
Wednesday, July 7, 2010
10 a.m. U.S. ET, 4 p.m. CET

Presentation: 35 minutes

Q & A: 10 minutes

About the Speaker

Michael J. Malecki, Ph.D., is a Product Director and head of biosimilars research at Decision Resources. Dr. Malecki specializes in conducting primary market research, identifying leading indicators and translating market findings into tactical and strategic objectives. Prior to joining the company, Dr. Malecki completed his doctorate in biological chemistry and molecular pharmacology at Harvard Medical School, where he was an American Heart Association Predoctoral Fellow.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.